0001437749-22-004679.txt : 20220228 0001437749-22-004679.hdr.sgml : 20220228 20220228172518 ACCESSION NUMBER: 0001437749-22-004679 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20220228 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220228 DATE AS OF CHANGE: 20220228 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOLIFE SOLUTIONS INC CENTRAL INDEX KEY: 0000834365 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 943076866 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36362 FILM NUMBER: 22691639 BUSINESS ADDRESS: STREET 1: 3303 MONTE VILLA PARKWAY STREET 2: SUITE 310 CITY: BOTHELL STATE: WA ZIP: 98021 BUSINESS PHONE: 4254011400 MAIL ADDRESS: STREET 1: 3303 MONTE VILLA PARKWAY STREET 2: SUITE 310 CITY: BOTHELL STATE: WA ZIP: 98021 FORMER COMPANY: FORMER CONFORMED NAME: BIOLIFE SOLUTION INC DATE OF NAME CHANGE: 20030113 FORMER COMPANY: FORMER CONFORMED NAME: CRYOMEDICAL SCIENCES INC DATE OF NAME CHANGE: 19920703 8-K 1 bioli20220228_8k.htm FORM 8-K bioli20220228_8k.htm
false 0000834365 0000834365 2022-02-28 2022-02-28
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): February 28, 2022
 
BIOLIFE SOLUTIONS, INC.
(Exact name of registrant as specified in its charter)
 
Delaware
  
001-36362
  
94-3076866
(State or other jurisdiction of
incorporation)
  
(Commission File Number)
  
(IRS Employer Identification No.)
 
3303 Monte Villa Parkway,
Bothell, WA 98021
(Address of principal executive offices) (Zip Code)
 
Registrant’s telephone number, including area code: (425) 402-1400
 
N/A
(Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
Trading symbol
Name of exchange on which registered
BioLife Solutions, Inc. Common Stock
BLFS
NASDAQ Capital Market
 
 
 
 
Item 2.02         Results of Operations and Financial Condition.
 
On February 28, 2022, BioLife Solutions, Inc. issued a press release announcing financial results and operational highlights for the fourth quarter and year ended December 31, 2021. A copy of the press release is furnished as Exhibit 99.1 to this current report on Form 8-K.
 
Item 9.01         Financial Statements and Exhibits.
 
(d) Exhibits
 
Exhibit No.
  
Description
99.1
  
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)
 
 
 
 
SIGNATURE
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
BioLife Solutions, Inc.
  
     
Date: February 28, 2022
By:
/s/ Troy Wichterman
  
   
Name: Troy Wichterman
Title: Chief Financial Officer
  
 
 
 EX-99.1 2 ex_341274.htm EXHIBIT 99.1 ex_341274.htm

Exhibit 99.1

 biolife01.jpg

 

biolife02.jpg
 
 

BioLife Solutions Reports Unaudited Fourth Quarter and Full Year 2021 Financial Results

 

Record quarterly revenue of $37.3 million up 153% over Q4 2020, with organic revenue growth of 64% and biopreservation media revenue growth of 64%

 

Record full year revenue of $119.2 million up 148% over 2020, with organic revenue growth of 37% and biopreservation media revenue growth of 39%

 

Initial guidance for 2022 total revenue at $159.5 million to $171 million, reflecting overall growth of 34% to 44% over 2021 and organic growth of 28% to 39%

 

Conference call begins at 4:30 p.m. Eastern time today

 

BOTHELL, Wash. (February 28, 2022) – BioLife Solutions, Inc. (Nasdaq: BLFS) (“BioLife” or the “Company”), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapies (CGT) and the broader biopharma markets, today announced unaudited financial results for the three and 12 months ended December 31, 2021 and introduced 2022 revenue guidance.

 

Mike Rice, Chairman and CEO, commented, “Our team produced outstanding topline results for the 2021 fourth quarter and year. Demand for all our complementary platforms continued to grow as we cross-sold solutions to further penetrate existing customers and gained new customers in the CGT and broader biopharma markets. Our acquisitions of fast-growing assets are driving growth and complementing accelerating growth in demand for our biopreservation media products. In particular, our ULT freezer platform team doubled production and customer shipments from 2020 due to COVID-19 demand, shipping nearly 8,000 freezers in 2021.

 

“Our outlook for 2022 is for another exceptional year with growth in total revenue of 34% to 44%, including organic growth of 28% to 39%,” he added. “We continue to work through ULT freezer supplier and warranty issues and are confident that demand for our Stirling engine-based ULT freezers will continue to increase in 2022 and beyond, and that we can deliver high-quality products and provide stellar customer experiences.”

 

Operational Highlights

 

 

●

For the fourth quarter of 2021, we gained more than 235 new direct customers including 15 now using biopreservation media, 7 using ThawSTAR® systems, 11 now using evo® cold chain management services, 17 now using CBS cryogenic freezers and accessories, 159 now using Stirling ULT freezers and accessories, 14 now using SciSafe® biologic storage services and 12 now using Sexton cell processing products.

 

 
 

 biolife01.jpg

biolife02.jpg
 
 

●

For 2021, we added more than 700 new direct customers, compared with 218 new direct customers added in 2020.

 

 

●

Realized significant distributor pull-through to expand our end-customer base. Our two largest distributors alone sold and shipped our biopreservation media products to more than 4,200 unique end users in 2021.

 

 

●

For the fourth quarter of 2021, we processed 17 new U.S. FDA Drug Master File cross-reference requests, indicating the planned use of CryoStor® or HypoThermosol® in pending cell and gene therapy clinical trials. To date, our biopreservation media products have been used in more than 530 customer clinical applications, up from 450 at the end of 2020. Our proprietary biopreservation media products are embedded in the manufacturing process of eight approved cell or gene therapies and in at least 10 additional therapies for which regulatory filings are expected to be submitted in 2022 and 2023. We estimate potential annual biopreservation media revenue per approved commercial application to range from $500,000 to $2,000,000.

 

 

●

Biostorage services demand surged in 2021, with revenue growth driven by increased storage of CAR T-cell therapies and COVID-19 vaccines. We supported this increase in demand by opening our first biorepository outside the USA in Amsterdam and by expanding two existing facilities in the USA.

 

 

●

Use of evo® cold chain by CGT end customers continued to increase in 2021, with nearly 4,000 courier partner shipments to more than 600 unique destinations and shipment volume up 81% over 2020. In addition to use of our evo cold chain platform by a global pharma company for transporting an approved CAR-T cell therapy, validation is now underway by a second global pharma company for use in transporting two approved CAR-T cell therapies. Both companies are currently served by a legacy cold chain logistics services provider.

 

Fourth Quarter and Full Year 2021 Financial Results

 

BioLife Solutions is presenting various financial metrics under U.S. Generally Accepted Accounting Principles (GAAP) and as adjusted (non-GAAP). A reconciliation of GAAP to non-GAAP metrics appears at the end of this news release.

 

REVENUE

 

 

●

Total revenue for the fourth quarter of 2021 was $37.3 million, an increase of 153% from $14.7 million for the fourth quarter of 2020, with organic revenue growth of 64%. COVID-19 related revenue accounted for approximately 15% of total revenue.

 

 

o

Cell processing platform revenue was $14.8 million, up $6.6 million, or 81%, over the same period in 2020. Organic growth was 64%.

 

 

o

Freezers and Thaw Systems platform revenue was $16.6 million, up $12.3 million, or 285%, over the same period in 2020. COVID-19 related revenue accounted for approximately 15% of the freezer and thaw systems platform revenue. Organic growth was 13%.

 

Page 2 of 12
 

 

 biolife01.jpg

biolife02.jpg

 

 

o

Storage and Storage Services platform revenue was $5.9 million, up $3.6 million, or 164%, over the same period in 2020. COVID-19 related revenue accounted for approximately 50% of the storage and storage services platform revenue. Organic growth was 164%.

 

 

●

Total revenue for 2021 was $119.2 million, an increase of 148% from $48.1 million for 2020, with organic revenue growth of 37%. COVID-19 related revenue accounted for approximately 15% of total revenue.

 

 

o

Cell processing platform revenue was $45.0 million, up $14.0 million, or 45%, over 2020. Organic growth was 39%.

 

 

o

Freezers and Thaw Systems platform revenue was $56.6 million, up $43.1 million, or 318%, over 2020. COVID-19 related revenue accounted for approximately 20% of the freezer and thaw systems platform revenue. Organic growth was 30%.

 

 

o

Storage and Storage Services platform revenue was $17.6 million, up $14.0 million, or 389%, over 2020. COVID-19 related revenue accounted for approximately 40% of the storage and storage services platform revenue. Organic growth was 54%.

 

GROSS MARGIN

 

 

●

Gross margin (GAAP) for the fourth quarter of 2021 was 15% compared with 50% for the fourth quarter of 2020. Adjusted gross margin (non-GAAP) for the fourth quarter of 2021 was 18% compared with 54% for the fourth quarter of 2020. The decline in gross margin resulted from a shift in product mix with our acquisition of Global Cooling, Inc., including charges of $6.5 million, or 17% of total revenue, related to an increased warranty accrual estimate, supply chain surcharges and inventory write-offs associated with the Stirling ULT freezers. In addition, we had $1.5 million in one-time and transitory impacts to gross margin across the other product platforms, including channel mix and higher than usual scrap. Excluding the $8.0 million of impacts mentioned above, adjusted gross margin for the fourth quarter of 2021 was approximately 39%.

 

Regarding the latent supplier and quality issues we inherited with our acquisition of Global Cooling, our team has implemented numerous production, quality and supplier management-related process improvements and controls. We expect these initiatives will continue to improve gross margins for our ULT freezer platform and our total business throughout 2022.

 

 

●

Gross margin (GAAP) for 2021 was 29% compared with 52% for 2020. Adjusted gross margin (non-GAAP) for 2021 was 33% compared with 58% for 2020. Gross margin for 2021 was negatively impacted by the aforementioned Stirling ULT freezer issues.

 

OPERATING EXPENSE

 

 

●

Operating expense (GAAP) for the fourth quarter of 2021 was $55.5 million compared with $19.5 million for the fourth quarter of 2020. Adjusted operating expense (non-GAAP) for the fourth quarter of 2021 was $20.1 million compared with $8.2 million for the fourth quarter 2020.

 

Page 3 of 12
 

 

 biolife01.jpg

biolife02.jpg

 

 

●

Operating expense (GAAP) for 2021 was $154.0 million compared with $53.7 million for 2020. Adjusted operating expense (non-GAAP) for 2021 was $59.6 million compared with $27.6 million for 2020.

 

 

●

The increase in operating expense for both periods was primarily due to the acquisitions of Global Cooling and Sexton and the recognition of a full year of operating expense for SciSafe, which was acquired in the fourth quarter of 2020. In addition, operating expenses in both periods increased due to opening three new biorepository facilities, increased accounting costs related to becoming a Large Accelerated Filer and higher personnel costs, including non-cash stock compensation expense.

 

OPERATING INCOME/(LOSS)

 

 

●

Operating loss (GAAP) for the fourth quarter of 2021 was $18.2 million compared with operating loss of $4.7 million for the fourth quarter of 2020. Adjusted operating loss (non-GAAP) for the fourth quarter of 2021 was $13.2 million compared with adjusted operating loss of $255,000 for the fourth quarter of 2020.

 

 

●

Operating loss (GAAP) for 2021 was $34.9 million compared with operating loss of $5.6 million for 2020. Adjusted operating loss (non-GAAP) for 2021 was $20.7 million compared with adjusted operating income of $293,000 for 2020.

 

NET INCOME/(LOSS)

 

 

●

Net loss (GAAP) for the fourth quarter of 2021 was $15.2 million compared with net loss of $2.1 million for the fourth quarter of 2020. Adjusted net loss (non-GAAP) for the fourth quarter of 2021 was $13.3 million compared with adjusted net loss of $256,000 for the fourth quarter of 2020.

 

 

●

Net loss (GAAP) for 2021 was $8.4 million compared with net income of $2.7 million for 2020. Adjusted net loss (non-GAAP) for 2021 was $21.2 million compared with adjusted net income of $351,000 for 2020.

 

 

EARNINGS/(LOSS) PER SHARE

 

 

●

Basic and diluted loss per share (GAAP) for the fourth quarter of 2021 was $0.37 compared with basic and diluted loss per share of $0.06 for the fourth quarter of 2020.

 

 

●

Basic loss per share (GAAP) for 2021 was $0.22 compared with basic earnings per share of $0.09 for 2020. Diluted loss per share (GAAP) for 2021 was $0.22 compared with diluted loss per share of $0.03 for 2020.

 

Page 4 of 12
 

 

 biolife01.jpg

biolife02.jpg

 

ADJUSTED EBITDA

 

 

●

Adjusted EBITDA, a non-GAAP measure, for the fourth quarter of 2021 was negative $5.5 million compared with positive $2.5 million for the fourth quarter of 2020.

 

 

●

Adjusted EBITDA, a non-GAAP measure, for 2021 was negative $1.1 million compared with positive $8.3 million for 2020. These results include the impact of $8.0 million from the above-mentioned extraordinary expenses and transitory impacts. We also had approximately $943,000 in operating expense related to the buildout of biorepository facilities.

 

CASH

 

 

●

Cash, cash equivalents and restricted cash as of December 31, 2021 were $69.9 million.

 

2022 Revenue Guidance

 

Management is providing initial 2022 revenue guidance, which is based on expectations for our existing business.

 

Total revenue for 2022 is expected to range from $159.5 million to $171.0 million, reflecting year-over-year growth of 34% to 44% and organic growth of 28% to 39%. COVID-19 related revenue is expected to account for approximately 8% to 9% of total revenue.

 

Total revenue expectations for 2022 include the following platform contributions:

 

 

●

Cell processing platform: $64.0 million to $67.5 million, an increase of 42% to 50% over 2021 and organic growth of 30% to 35%. This includes biopreservation media and Sexton products.

 

 

●

Freezers and Thaw Systems platform: $74.0 million to $77.5 million, an increase of 31% to 37% over 2021 and organic growth of 28% to 39%. COVID-19 related revenue is expected to account for approximately 5% of the freezer and thaw systems platform revenue.

 

 

●

Storage and Storage Services platform: $21.5 million to $26.0 million, an increase of 22% to 48% over 2021 and organic growth of 22% to 48%. COVID-19 related revenue is expected to account for approximately 40% to 50% of the storage and storage services platform revenue. This includes evo® cold chain rental and SciSafe biostorage services revenues.

 

Although the company does not provide guidance below the revenue line, we expect positive 2022 full year adjusted EBITDA.

 

Expects to File Form 12b-25 for Extension of Filing Deadline for 2021 Form 10-K

 

The Company also announced today that it expects to file a notification of late filing on Form 12b-25 with the Securities and Exchange Commission, which provides an automatic 15-day extension of the filing deadline for its Annual Report on Form 10-K for the fiscal year ended December 31, 2021 (the “2021 Form 10-K”) to March 16, 2022.

 

Page 5 of 12
 

 

 biolife01.jpg

biolife02.jpg

 

The financial data presented for the year ended December 31, 2021 should be considered preliminary and could be subject to change as the Company’s independent registered public accounting firm has not completed its audit. The Company anticipates that the Form 10-K for the year ended December 31, 2021 will be filed by March 16, 2022 or as soon as practicable.

 

Conference Call & Webcast

 

Management will discuss the Company's financial results and provide a general business update on a conference call and live webcast today at 4:30 p.m. ET (1:30 p.m. PT).

 

To access the webcast, log onto the Investor Relations page of the BioLife Solutions website at http://www.biolifesolutions.com/earnings. Alternatively, you may access the live conference call by dialing (844) 825-0512 or (315) 625-6880 and use Conference ID 9584819. A webcast replay will be available approximately two hours after the completion of the call and will be archived on http://www.biolifesolutions.com/ for 90 days.

 

About BioLife Solutions

 

BioLife Solutions is a leading supplier of class-defining bioproduction tools and services for the cell and gene therapy and broader biopharma markets. Our tools portfolio includes our proprietary CryoStor® and HypoThermosol® biopreservation media for shipping and storage, the ThawSTAR® family of automated, water-free thawing products, evo® cold chain management system,  high capacity cryogenic storage freezers, Stirling Ultracold mechanical freezers, SciSafe biologic storage services, and Sexton Biotechnologies cell processing tools. For more information, please visit www.biolifesolutions.com, www.scisafe.com, www.stirlingultracold.com, or www.sextonbio.com and follow BioLife on Twitter.

 

Cautions Regarding Forward Looking Statements

 

Except for historical information contained herein, this press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements concerning the expected financial performance of the company following the completion of its 2019, 2020 and 2021 acquisitions and giving effect to the COVID-19 pandemic, the company's ability to implement its business strategy and anticipated business and operations, in particular following its recent acquisitions, the expected synergies between the company and the companies and products that it has recently acquired, the company’s ability to realize all or any of the anticipated benefits associated with its recent acquisitions, the potential utility of and market for the company's products and services and the company’s ability to cross sell its products and services, guidance for financial results for 2022, including regarding revenue of its recently acquired products, and potential revenue growth and changes in gross margin, adjusted gross margin and adjusted EBITDA gross margin, and potential market expansion, including with consideration to our recent acquisitions and giving effect to the COVID-19 pandemic, the company's anticipated future growth strategy, including the acquisition of synergistic cell and gene therapy manufacturing tools and services or technologies, regulatory approvals and/or commercial manufacturing of our customers' products, and potential customer revenue and our ability to timely file our annual report on Form 10-K. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including among other things, unexpected costs, charges or expenses resulting from our recent acquisitions, market adoption of the company’s products (including the company’s recently acquired products), the ability of our recent acquisitions to be accretive on the company’s financial results, the ability of the company to continue to implement its business strategy, uncertainty regarding third-party market projections, market volatility, competition, litigation, the impact of the COVID-19 pandemic, and those other factors described in our risk factors set forth in our filings with the Securities and Exchange Commission from time to time, including our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.

 

Page 6 of 12
 

 

 biolife01.jpg

biolife02.jpg

 

Non-GAAP Measures of Financial Performance:

 

To supplement our financial statements, which are presented on the basis of U.S. generally accepted accounting principles (GAAP), the following non-GAAP measures of financial performance are included in this release: adjusted gross profit and gross margin, adjusted operating expenses, adjusted operating income/(loss), adjusted net income/(loss), earnings before interest, taxes, depreciation and amortization (EBITDA), and adjusted EBITDA. A reconciliation of GAAP to adjusted non-GAAP financial measures is included as an attachment to this press release. When analyzing the Company's operating results, investors should not consider non-GAAP measures as substitutes for the comparable financial measures prepared in accordance with GAAP.

 

 

Media & Investor Relations
 

At the Company

 

Troy Wichterman

Chief Financial Officer

(425) 402-1400

twichterman@biolifesolutions.com

 

 

Investors

 

LHA Investor Relations

Jody Cain

(310) 691-7100

jcain@lhai.com

 

Page 7 of 12
 

 

biolife01.jpg

biolife02.jpg

 

BIOLIFE SOLUTIONS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited, amounts in thousands, except share and per share amounts)

 

   

Three Months Ended

    

Year Ended

  
   

December 31,

    

December 31,

  

(In thousands, except per share and share data)

  

2021

    

2020

    

2021

    

2020

  
                                 

Product revenue

   $ 31,468     $ 12,520     $ 101,913     $ 44,540  

Service revenue

     3,400       1,752       9,817       1,752  

Rental revenue

     2,436       454       7,426       1,795  

Total revenue

     37,304       14,726       119,156       48,087  

Costs and operating expenses:

                                

Cost of product, rental, and service revenue (exclusive of Intangible asset amortization)

     30,440       6,753       81,408       20,646  

Research and development

     3,569       1,854       11,819       6,720  

Sales and marketing

     4,767       1,883       13,996       6,413  

General and administrative

     12,039       4,684       34,097       14,607  

Intangible asset amortization

     2,863       933       8,202       3,033  

Acquisition costs

     20       251       1,636       668  

Change in fair value of contingent consideration

     1,790       3,103       2,875       1,575  

Total operating expenses

     55,488       19,461       154,033       53,662  

Operating loss

     (18,184 )     (4,735 )     (34,877 )     (5,575 )
                                 

Other income (expense), net

                                

Change in fair value of warrant liability

     -       (866 )     (121 )     3,601  

Change in fair value of investments

     -       209       -       1,319  

Interest (expense) income, net

     (101 )     (1 )     (432 )     58  

Other expense

     299       -       290       -  

Gain on acquisition of Sexton Biotechnologies, Inc.

     -       -       6,451       -  

Total other income (expense)

     198       (658 )     6,188       4,978  
                                 

Loss before income tax benefit

     (17,986 )     (5,393 )     (28,689 )     (597 )

Income tax benefit

     2,766       3,264       20,306       3,264  

Net (loss) income

   $ (15,220 )   $ (2,129 )   $ (8,383 )   $ 2,667  
                                 

Net (loss) income attributable to common shareholders

                                

Basic

   $ (0.37 )   $ (0.06 )   $ (0.22 )   $ 0.09  

Diluted

   $ (0.37 )   $ (0.06 )   $ (0.22 )   $ (0.03 )

Weighted average shares used to compute loss per share attributable to common shareholders:

                                

Basic and Diluted

     41,675,256       32,960,437       38,503,944       27,306,258  

 

Page 8 of 12
 

 

 biolife01.jpg

biolife02.jpg

 

BIOLIFE SOLUTIONS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

(Unaudited, amounts in thousands, except per share amounts)

 

   

Three Months Ended

    

Year Ended

  
   

December 31,

    

December 31,

  

(In thousands)

  

2021

    

2020

    

2021

    

2020

  
                                 

NET INCOME/(LOSS)

   $ (15,220 )   $ (2,129 )   $ (8,383 )   $ 2,667  

Other comprehensive income/(loss)

     (119 )     -       (282 )     -  

COMPREHENSIVE INCOME/(LOSS)

   $ (15,339 )   $ (2,129 )   $ (8,665 )   $ 2,667  

 

 

BIOLIFE SOLUTIONS, INC.

CONDENSED CONSOLIDATED BALANCE SHEET INFORMATION

(Unaudited, amounts in thousands)

 

   

December 31,

    

December 31,

  

(In thousands)

  

2021

    

2020

  

Cash, cash equivalents and restricted cash

   $ 69,870     $ 90,456  

Accounts receivable, net

     23,217       8,006  

Inventories

     28,345       11,602  

Total current assets

     125,859       114,712  

Total assets

     552,604       234,829  
                 

Accounts Payable

     14,945       3,672  

Total current liabilities

     39,970       15,573  

Total liabilities

     71,853       29,583  

Total shareholders' equity

   $ 480,751     $ 205,246  

 

 

BIOLIFE SOLUTIONS, INC.

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS INFORMATION

(Unaudited, amounts in thousands)

 

   

Year Ended

  
   

December 31,

  

(In thousands)

  

2021

    

2020

  

Net cash (used in) provided by operating activities

   $ (4,836 )   $ 6,515  

Net cash used in investing activities

     (12,642 )     (23,731 )

Net cash (used in) provided by financing activities

     (2,826 )     101,224  

Effects of currency translation

     (282 )     -  

Net increase (decrease) in cash, cash equivalents and restricted stock

   $ (20,586 )   $ 84,008  

 

Page 9 of 12
 

 

 biolife01.jpg

biolife02.jpg

 

BIOLIFE SOLUTIONS, INC.

RECONCILIATION OF GAAP GROSS PROFIT TO NON-GAAP (ADJUSTED) GROSS PROFIT

(Unaudited, amounts in thousands)

 

   

Three Months Ended

    

Year Ended

  
   

December 31,

    

December 31,

  

(In thousands)

  

2021

    

2020

    

2021

    

2020

  

GAAP GROSS PROFIT

   $ 5,771     $ 7,387     $ 34,847     $ 25,113  

GAAP GROSS MARGIN

     15

%

     50

%

     29

%

     52

%
                                 

ADJUSTMENTS TO GROSS PROFIT:

                                

Inventory step-up

     -       21       1,130       411  

Intangible asset amortization

     1,093       586       2,901       2,328  

ADJUSTED GROSS PROFIT

   $ 6,864     $ 7,994     $ 38,878     $ 27,852  

ADJUSTED GROSS MARGIN

     18

%

     54

%

     33

%

     58

%

 

 

BIOLIFE SOLUTIONS, INC.

RECONCILIATION OF GAAP OPERATING EXPENSES TO NON-GAAP (ADJUSTED) OPERATING EXPENSES

(Unaudited, amounts in thousands)

 

   

Three Months Ended

    

Year Ended

  
   

December 31,

    

December 31,

  

(In thousands)

  

2021

    

2020

    

2021

    

2020

  

GAAP OPERATING EXPENSES

   $ 55,488     $ 19,461     $ 154,033     $ 53,662  
                                 

ADJUSTMENTS TO OPERATING EXPENSES:

                                

Cost of product, rental, and service revenue

     (30,440 )     (6,753 )     (81,408 )     (20,646 )

Acquisition costs

     (20 )     (251 )     (1,636 )     (668 )

Intangible asset amortization

     (2,863 )     (933 )     (8,202 )     (3,033 )

Loss on disposal of assets

     (284 )     (172 )     (308 )     (181 )

Change in fair value of contingent consideration

     (1,790 )     (3,103 )     (2,875 )     (1,575 )

ADJUSTED OPERATING EXPENSES

   $ 20,091     $ 8,249     $ 59,604     $ 27,559  

 

Page 10 of 12
 

 

 biolife01.jpg

biolife02.jpg

 

BIOLIFE SOLUTIONS, INC.

RECONCILIATION OF GAAP OPERATING INCOME (LOSS) TO NON-GAAP (ADJUSTED) OPERATING INCOME (LOSS)

(Unaudited, amounts in thousands)

 

   

Three Months Ended

    

Year Ended

  
   

December 31,

    

December 31,

  

(In thousands)

  

2021

    

2020

    

2021

    

2020

  

GAAP OPERATING INCOME/(LOSS)

   $ (18,184 )   $ (4,735 )   $ (34,877 )   $ (5,575 )
                                 

ADJUSTMENTS TO OPERATING INCOME:

                                

Inventory step-up

     -       21       1,130       411  

Acquisition costs

     20       251       1,636       668  

Intangible asset amortization

     2,863       933       8,202       3,033  

Loss on disposal of assets

     284       172       308       181  

Change in fair value of contingent consideration

     1,790       3,103       2,875       1,575  

ADJUSTED OPERATING INCOME/(LOSS)

   $ (13,227 )   $ (255 )   $ (20,726 )   $ 293  

 

BIOLIFE SOLUTIONS, INC.

RECONCILIATION OF GAAP NET INCOME (LOSS) TO NON-GAAP (ADJUSTED) NET INCOME (LOSS)

(Unaudited, amounts in thousands)

 

   

Three Months Ended

    

Year Ended

  
   

December 31,

    

December 31,

  

(In thousands)

  

2021

    

2020

    

2021

    

2020

  

GAAP NET INCOME/(LOSS)

   $ (15,220 )   $ (2,129 )   $ (8,383 )   $ 2,667  
                                 

ADJUSTMENTS TO NET INCOME/(LOSS):

                                

Inventory step-up

     -       21       1,130       411  

Acquisition costs

     20       251       1,636       668  

Intangible asset amortization

     2,863       933       8,202       3,033  

Loss on disposal of assets

     284       172       308       181  

Change in fair value of contingent consideration

     1,790       3,103       2,875       1,575  

Change in fair value of investments

     -       (209 )     -       (1,319 )

Change in fair value of warrant liability

     -       866       121       (3,601 )

Gain on acquisition of Sexton Biotechnologies, Inc.

     -       -       (6,451 )     -  

Gain on PPP loan extinguishment

     (284 )     -       (284 )     -  

Income tax benefit

     (2,766 )     (3,264 )     (20,306 )     (3,264 )

ADJUSTED NET INCOME/(LOSS)

   $ (13,313 )   $ (256 )   $ (21,152 )   $ 351  

 

Page 11 of 12
 

 

 biolife01.jpg

biolife02.jpg

 

BIOLIFE SOLUTIONS, INC.

RECONCILIATION OF GAAP NET INCOME (LOSS) TO NON-GAAP (ADJUSTED) EBITDA

(Unaudited, amounts in thousands)

 

   

Three Months Ended

    

Year Ended

  
   

December 31,

    

December 31,

  

(In thousands)

  

2021

    

2020

    

2021

    

2020

  

GAAP NET INCOME/(LOSS)

   $ (15,220 )   $ (2,129 )   $ (8,383 )   $ 2,667  
                                 

ADJUSTMENTS:

                                

Interest expense/(income), net

     101       1       432       (58 )

Income tax benefit

     (2,766 )     (3,264 )     (20,306 )     (3,264 )

Depreciation

     1,314       581       4,311       2,035  

Intangible asset amortization

     2,863       933       8,202       3,033  

EBITDA

   $ (13,708 )   $ (3,878 )   $ (15,744 )   $ 4,413  
                                 

OTHER ADJUSTMENTS:

                                

Share-based compensation (non-cash)

     6,427       2,164       15,319       5,981  

Inventory step-up

     -       21       1,130       411  

Acquisition costs

     20       251       1,636       668  

Loss on disposal of assets

     284       172       308       181  

Change in fair value of contingent consideration

     1,790       3,103       2,875       1,575  

Change in fair value of investments

     -       (209 )     -       (1,319 )

Change in fair value of warrant liability

     -       866       121       (3,601 )

Gain on acquisition of Sexton Biotechnologies, Inc.

     -       -       (6,451 )     -  

Gain on PPP loan extinguishment

     (284 )     -       (284 )     -  

ADJUSTED EBITDA

   $ (5,471 )   $ 2,490     $ (1,090 )   $ 8,309  

 

# # #

 

Page 12 of 12
 EX-101.SCH 3 blfs-20220228.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink EX-101.DEF 4 blfs-20220228_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 blfs-20220228_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity [Domain] Legal Entity [Axis] Document Information [Line Items] Document Information [Table] Document, Type Document, Period End Date Entity, Registrant Name Entity, Incorporation, State or Country Code Entity, File Number Entity, Tax Identification Number Entity, Address, Address Line One Entity, Address, City or Town Entity, Address, State or Province Entity, Address, Postal Zip Code City Area Code Local Phone Number Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Entity, Emerging Growth Company Title of 12(b) Security Trading Symbol Security Exchange Name Amendment Flag Entity, Central Index Key EX-101.PRE 6 blfs-20220228_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 biolife01.jpg begin 644 biolife01.jpg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end GRAPHIC 8 biolife02.jpg begin 644 biolife02.jpg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end XML 9 R1.htm IDEA: XBRL DOCUMENT v3.22.0.1
Document And Entity Information
Feb. 28, 2022
Document Information [Line Items]  
Entity, Registrant Name BIOLIFE SOLUTIONS, INC.
Document, Type 8-K
Document, Period End Date Feb. 28, 2022
Entity, Incorporation, State or Country Code DE
Entity, File Number 001-36362
Entity, Tax Identification Number 94-3076866
Entity, Address, Address Line One 3303 Monte Villa Parkway
Entity, Address, City or Town Bothell
Entity, Address, State or Province WA
Entity, Address, Postal Zip Code 98021
City Area Code 425
Local Phone Number 402-1400
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity, Emerging Growth Company false
Title of 12(b) Security BioLife Solutions, Inc. Common Stock
Trading Symbol BLFS
Security Exchange Name NASDAQ
Amendment Flag false
Entity, Central Index Key 0000834365
XML 10 bioli20220228_8k_htm.xml IDEA: XBRL DOCUMENT 0000834365 2022-02-28 2022-02-28 false 0000834365 8-K 2022-02-28 BIOLIFE SOLUTIONS, INC. DE 001-36362 94-3076866 3303 Monte Villa Parkway Bothell WA 98021 425 402-1400 false false false false false BioLife Solutions, Inc. Common Stock BLFS NASDAQ EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( ">+7%0'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " GBUQ4&'+(Z>T K @ $0 &1O8U!R;W!S+V-O&ULS9+/ M2L0P$(=?17)OITU1)'1S43PI""XHWD(RNQML_I",M/OVMG&WB^@#>,S,+]]\ M ]/K*'1(^)Q"Q$06\]7D!I^%CAMV((H"(.L#.I7K.>'GYBXDIVA^ICU$I3_4 M'H$WS0TX)&44*5B 55R)3/9&"YU044@GO-$K/GZFH<",!AS0H:<,;=T"D\O$ M>)R&'BZ !4:87/XNH%F)I?HGMG2 G9)3MFMJ',=Z[$INWJ&%MZ?'E[)N97TF MY37.O[(5=(RX8>?)K]W=_?:!2=YP7C6\XK=;S@6_%FWWOKC^\+L(NV#LSOYC MX[.@[.'77<@O4$L#!!0 ( ">+7%297)PC$ 8 )PG 3 >&PO=&AE M;64O=&AE;64Q+GAM;.U:6W/:.!1^[Z_0>&?V;0O&-H&VM!-S:7;;M)F$[4X? MA1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4\GA@ MV2_;UKNW+][@5S(D$4$P&:>O\, *I4Q>M5II ,,X?+&A T%116F]?(+3E'S/X%/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53"Q,!J9S]6:\?1 MTDB @LE]E 6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@X_%X.+;+THMP M' 3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ-4T_3]WW?ZYMHG J-6T_3:W?= MTXZ)QJW0> V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E0-,@ %AP M=M;,T@.67BGZ=90:V1V[W4%<\%CN.8D1_L;%!-9ITAF6-$9RG9 %#@ WQ-%, M4'RO0;:*X,*2TER0UL\IM5 :")K(@?5'@B'%W*_]]9>[R:0S>IU].LYKE']I MJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+ GQ^R-;88C'(CN]WV6'WV3T=N(]>IP+,BUY1&)$6?R"VZ MY!$XM4D-,A,_")V&F&I0' *D"3&6H8;XM,:L$> 3?;>^",C?C8CWJV^:/5>A M6$G:A/@01AKBG'/F<]%L^P>E1M'V5;SC MFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0KH)[ ?_1VC?"J_B"P#E_ M+GW/I>^Y]#VATK\>WZV22$KYI9+2,6D$N!LT$DN/R+RO JQ GH9%LE" M0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F.$KT ML@'37[]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1N0K3 M4I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B(>ZAAIC/PT.' M>7M?F&>5QE T%&ULK"0L1K=@N-?Q+!3@9& MH >#KU$"\E)58#%;Q@,KD*)\ M3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG":9@39ZO*WF6QP54=SU5;\K"^ M:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON>;G*YZ(G;ZEW?! M8/+]<,E'#^4[YU_T74.N?O;=X_INDSM(3)QYQ1$!=$4"(Y4U#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX#7N83 M+$.D?L%]BHJ $:MBOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4JUJE9"L1/TL' M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5 MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$% @ M)XM<5(2%IX5"! :A !@ !X;"]W;W)KF,0!JXG-.,Y0_OT> M!T@8;3BAO6B&:I31KRPT3 M\":6*J4:;M7*RC:*T:AHE":6:]M=*Z5^&JMS0-KT-_0%0N8_K:9*[BS2I6(ITQD7 JB6'S?&CJ?1V[' M-"AJ?.=LFYV4B1G*4LHW<^-']RW;$+&$A=I(4+C\9&.6)$8).'X<1%MEGZ;A M:?FH/BD&#X-9THR-9?+*([V^;_5:)&(QS1/](K=_L<. ;HQ>*).L^$^V^[J= MFQ8)\TS+]- 8"%(N]E?Z?IB(DP;>[9D&[J&!6W#O.RHH'ZBF@[Z26Z),;5 S MA6*H16N X\*L2J 5O.703@\>9)C#)&LR%!%Y%)KK'?'%?K5AUOJ6ADY,52L\ M"([V@NX9P0E;MHG;NR*N[;J_-K> K01T2T"WT/.: $^HR#]3J$5\S=+L7Z0/ MK^S#*_KHG.EC/^XK\L)6/-.*0F\SFK*ZP>-"(_]YZD\>2? \_;;PGV?!%?%G MXS:"V"D1.ZCR<1JNR&*WJ27#V_>NOR 4-R7%S844]$J^B*4:B-5$2I7)-# 1Z0B8YD+K79PC6IYQ;>?:ZWI=;,YZ)5#O(J %?2=^!"O+8Q[N<^P\'BYY MU[GV[-MNK]M%^.Y*OKN+^(91I%B6E052&,"SJ%U(7-+S;(\\20%!\9TG"25S MJMZV=(?0.G;EIO;'>,?&4"'X%G);;Z:XWDCJ->Q8&-N)TSL?8RLS8Z[D3R[" MVLEL$'T=8FR5R3ONQ]CF,M,T(7_SS=E\;9"\Z]FN@\%5NX.#NWJQAD/XYCF/ M@@MTW!L,I-H#'-S$IS*$.9FOI<#V,:)J/W!P%W]57&LF8&+2 M-!<'Z\AJJ7"AF"89PY"J7<#!C3J0"0^YYF)%GB"^%:=)+0^NTLA36;Z#V_5< ML>L0IH=!@A4?,@LF(J;(< U[N(R)X_Z^_(,$+,PA M%VJ9&I1&7$YYS @$;EZD3_$)TRYR"O;A0,OP#4.N-@ 7]^J%HI&9Q6"7+F5M M4C0(C*:3 ",Y^:;'O?DX6^3Q/5Q3L6)GO[<;A&;#X&'X%6.J7-[%37H(*1 5 M:3!)Z*J6!1=HC*W*YUWE['Z]9N0=;) MR=&+7%2?H!OPL0( .(, - >&PO9KEMWDOSAR+DCO9*ZW="C<\W[)&D/1ZY8 M^\XT7'ND,E8QYU5;)VUC.2M;<%(R6=[<9(EB0M-BK3MUIUQ+#J;3;D-O:%*L M*Z//EI0&@U_*%">/3&[HEDFQMV)8RY20IV!>@N%@I+'$>2I\0Q=@:9\"O @: ML!SC**&-!6,2,H3O_;C\&3!IK5>%E#/!)0V&8MTPY[C5=UX9%@_&%Q 9Y=VI M\0QKRTZ+Y2T].PP_/LG>V)+;.'36-/+T08I:*Q[V_LL)BS6; M_,C16/'DL\&D'+R!6TH>N77B<&GY85FSX[V;IJFO<,[+?Y#SGZUSS36W3%Z2 M]J/_-U?Y+8R3\?1<'-&K SI;"5R$&_H5[E=YYD#VG9!.Z%$[BK+D^L4Y]>$= MV_L+_"J^7U_RBG72[69P0\_R%UZ*3N7SJGNHR[CJ+'^&^VB1S;>PSR5TR7M> M;D?5UOM!)%[P6<<'')XC=\,31S"?@,41P+ \& /,)WAA>?ZG_:S0_00,X[:* M(BO49X7Z!*\8LAT^6)ZX3^Z?^$[S/$VS#*OH=AMEL,7JEF7P%X^&<0,/+ ]D M>ENM\6[C$_+Z'& ]?6U"L)WBDXCM%*\U(/&Z@4>>Q[N-Y0$/K O8[$#^>!Z8 MJ;A/FD)7,6[8"<:1/,<0F,7XC&894IT,/O'^8* \^>Q\ETWLJ.?]74_P$4$L#!!0 ( ">+7%27BKL

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end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.0.1 html 1 122 1 false 0 0 false 0 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.blfs.com/20220228/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false All Reports Book All Reports bioli20220228_8k.htm blfs-20220228.xsd blfs-20220228_def.xml blfs-20220228_lab.xml blfs-20220228_pre.xml ex_341274.htm http://xbrl.sec.gov/dei/2021q4 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "bioli20220228_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "local": [ "blfs-20220228_def.xml" ] }, "inline": { "local": [ "bioli20220228_8k.htm" ] }, "labelLink": { "local": [ "blfs-20220228_lab.xml" ] }, "presentationLink": { "local": [ "blfs-20220228_pre.xml" ] }, "schema": { "local": [ "blfs-20220228.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" ] } }, "elementCount": 26, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 122, "memberCustom": 0, "memberStandard": 0, "nsprefix": "blfs", "nsuri": "http://www.blfs.com/20220228", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "bioli20220228_8k.htm", "contextRef": "d20228K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "role": "http://www.blfs.com/20220228/role/statement-document-and-entity-information", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "bioli20220228_8k.htm", "contextRef": "d20228K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20220228/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20220228/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20220228/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document, Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20220228/role/statement-document-and-entity-information" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document, Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20220228/role/statement-document-and-entity-information" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity, Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20220228/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity, Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20220228/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity, Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20220228/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity, Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20220228/role/statement-document-and-entity-information" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity, Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20220228/role/statement-document-and-entity-information" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20220228/role/statement-document-and-entity-information" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity, Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20220228/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity, File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20220228/role/statement-document-and-entity-information" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity, Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20220228/role/statement-document-and-entity-information" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity, Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20220228/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity, Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20220228/role/statement-document-and-entity-information" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20220228/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20220228/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20220228/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20220228/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20220228/role/statement-document-and-entity-information" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20220228/role/statement-document-and-entity-information" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20220228/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20220228/role/statement-document-and-entity-information" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20220228/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 17 0001437749-22-004679-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-22-004679-xbrl.zip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end